Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT05456685 |
| Title | Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRalpha) Expressing, Platinum-sensitive Epithelial Ovarian Cancer |
| Recruitment | Active, not recruiting |
| Gender | female |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | ImmunoGen, Inc. |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | GBR | ESP | CAN | BEL |